Viz.ai, an AI-driven healthcare solutions leader, has partnered with Cleerly, a company focused on revolutionizing heart disease diagnostics, to integrate Cleerly's AI-enabled cardiovascular tools into the Viz.ai One platform. This collaboration, announced on September 4, 2024, aims to streamline the detection and treatment of heart disease, the leading global cause of death. Cleerly's advanced FDA-approved software uses coronary computed tomography angiography images and AI algorithms to detect ischemia, and stenosis, and quantify plaque, facilitating early diagnosis and personalized treatment. The Viz.ai One platform, already used in over 1,600 hospitals, will now offer enhanced cardiology services, providing healthcare teams with more accurate and timely patient data.
Viz.ai, which serves more than 1,700 hospitals across the U.S. and Europe, is known for using AI algorithms to expedite diagnosis and care coordination. Cleerly’s integration will help optimize care pathways by offering precision diagnostics, providing clinicians with comprehensive analyses of coronary artery disease. According to leaders from both organizations, this partnership signifies a shared commitment to expanding access to life-saving treatments and improving patient outcomes through AI-powered healthcare solutions. With this collaboration, both companies are poised to transform cardiovascular care, facilitating early detection of heart disease and enhancing clinical impact.
